Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent. I think it was a waste of time talking to management before this latest generation, now a bit better. I am not 100 percent confident, but risk/reward is good
No reason to my knowledge to discount all the insider support
I like the idea of a $600 market cap goal, either 2021 or 2022. I would factor in 15 million shares outstanding, but $40 works for me, I have a good position I hope to sell none before $18
That is why I am happy to be away from the years when I shot for homeruns, preservation of capital works for me as I have managed funds and individual stocks of around 20 to 25
delcath is not unique, but for all practical purpose should be seen as at least 15 million shares fully diluted but loads of cash at that point. I would think $600 million market cap with that factored in is a fair assessment. I am a little worried about the finish up of phase 3, but risk is more than factored in
I am not a stock technical guru, but it does not look appealing to the uneducated tech. The risk/reward though is outstanding, this is priced in for 6 month delay easy and if no delay, voila
I don't think p3 release was botched. I do want final results this year. Down the line at least 15 million shares outstanding. Based on history 500 million market cap can be challenged. So I see $25 as quite possible at some point. Maybe double of 25. Best case would include a decision to start a trial on colorectal related liver, if it is talked up convincingly. Then more than $1 billion market cap but this message board would likely be on fire
This is the biggest position I have had in delcath since 2012. The downside would be if this phase 3 fell apart, otherwise little risk until middle of next year when FDA weighs in
Gerard bought a large amount at $12.88, what a breath of fresh air compared to the former Simpson and of course warrants executed at $10 is all new compared to the old days
Adam is a respectable guy, but I am skeptical of his take. All the other stats look reasonable, when the time comes I might think delcath has only 90 percent chance of approval simply because FDA is the 300 pound gorilla
I am a big buyer today
I am a big buyer today
Probably update on p3 on 3/31 quarterly call.
I am not comfortable that wrapping up P3 is still a problem so will preliminary be by end of March or 1st week of April, I don't know. It is a risk and efficacy is an open question too, certainly some efficacy but we wait. On the other hand $17 or $18 is worth some money
I think it is premature to worry about the trading. I have some concerns fundamentally, but $30 seems very possible if P3 is reasonable. The smallest of my concerns though is safety of treatment, safety is super
I expect the price to go over $30 on just reasonably okay P3 reported
I have made nibble sells above $20, but given I sold afterhours some at $24.63, I may buy back a little as high as $22.50, I would not be completed surprised with $60 or more at any time in next 18 months
I am a slow seller and sold most of my little sales this morning at $22.84 coincidentally. All depending though, I think $1 billion market cap may be on the low side but I wait for a couple more rounds or so of news to see how it is shaping up
Of course that $600M was like for a blink of an eye as the old product was overhyped in our minds as it did not filter well. We saw too many times it was a market cap of $1 million to $5 million so thus I am happy for those in now with the big boys as at least the possibility of winning is real.
Neal and I have been associated with this stock way longer probably than anybody else, many years. I believe big money has taken this company serious for the first time in history. There is a new top person running things after a search was conducted. Top line data expected for this quarter. Submission to FDA 1st qtr 2022. Number one reason from experience that I like this is because big money likes it. I think at least 15 million shares fully diluted over time. One billion market cap seems possible but my guess would be if so in 2022.
Holding strong
a January presentation is now on website, well done and indicates plans to start trials for 2 indications this year
BTIG initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and price target of $23. The stock closed at $16.91 on Jan. 4.
The last post shown other than you appears to be me from months back. I hope it stays that way. Here and yahoo are sufficient as boards. It is really amazing how bad small investors have been. I still stick with the smartest people from the old days sold in 2010 and never looked back. Most small folks buying now are apparently not people that post.
We compete. Speaking of competition, the new guy bought at $13.25 about $100K. I remember Hobbs put $360K at one time on a offering, so Hobbs invested rather poorly. Interestingly of course gen 2 was developed under Hobbs and of course Simpson carried the company forward it could be argued with sheer guts and massive selfishness. This time though I think the stars have lined up.
Welcome I think I am the world champ with most posts in history on this company plus more separate trades over the years. It has been a learning experience. Rosalind's money has given this company more legitimacy than any time before. Money talks. The new hired head of company was a significant win as well.
Official 4.1 million, but that is misleading. It is I believe 6.5 million total if you count preferred that can be switched freely. There is an active ATM for up to 1 million plus 4 million warrants executable at $10. My guess is at least 15 million outstanding in the next year or so, but divide I believe $1 billion market cap by 15 million, $70 stock price is believable
It seemed like dead forever, but for once in 2019 I read the tea leaves correctly. I knew the reverse split had to pass first
I remember the name. The short answer is this company got bought out in 2019 by Rosalind. You won't see that in any press release or filing but that is what was done. Under their watch there was one last reverse split which did exactly as promised, it restored the company to Nasdaq. This company has quarterly calls again and multiple analysts asking questions. Impressive new head of company as Simpson was fired. There used to be long periods where market cap would be between $1 and $5 million. Yesterday had a $2 million volume trading. My guess that last happened during the completely unjustified runup in 2017.
Have only sold very lightly for months. Maybe my next portion $20. This thing seems to want a healthy market cap after years of almost nonexistent.
I am holding a lot of my shares at 68 percent profit, a lot better than my performance probably all the way back to 2010.
Could well be topline results by end of January or not much later. Right now, I am riding with the new guy. My impression is he would like to see a $1 billion market cap for delcath, but it may not be 2021. 2022, don't know.
Maybe you are a person to envy, I already did though for myself most of the traveling I want to do
Why Medellin if you don't mind?
Just curious. I know you are a Jew, but I am ignorant as to why the words Medellin Israel
I was wondering myself
Could be $25 to $30 by Christmas 2021 roughly. It could go crazy whenever on approval, more folks will be talking on the boards later on this stuff. In fact when investors get excited, could be January 2021 if results are thought to be then.
It is amazing that most people still think this company is a scam. On the contrary when the word scam was fairly descriptive, often you couldn't be the excited people away
Old timers mostly don't realize that Rosalind essentially bought out the old delcath. This new hire comes from a relatively successful little biotech, I should think folks would take note.
I would temporarily rate above $12 as a little pricey given the environment of knuckleheaded leadership such as the U.K. shutting stuff down